Further inquiry note: Hannes Roither, PALFINGER AG Company Spokesperson Phone +43 662 46 84-2260 mailto: h.roither@palfinger.com www.palfinger.com Branche: Machine Manufacturing ISIN: AT0000758305 WKN: 919964 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official market ...
Berlin (ots/PRNewswire) - - For non-US Healthcare Media and non-UK Healthcare Media - New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a ...
Ingelheim, Germany (ots/PRNewswire) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS-Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with ...
Further inquiry note: USU AG Internationalization & Partner, Marc Kothé, Phone.: +49.69.430 53 644 , Mobile: +49.173.310 3435 , Fax: +49.69.430 53 645, m.kothe@usu.de Corporate Communications, Dr. Thomas Gerick, Phone.: +49.7141.4867-440 , Mobile: +49.178.555.6664 , Fax: +49.7141.4867-909, t.gerick@usu.de http://www.usu-ag.com (english) , http://www.usu.de ...
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official dealing ...
Further inquiry note: Stephan Haas Investor Relations Manager Telefon: +49(0)7123 724-137 E-Mail: stephan.haas@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Düsseldorf / free trade Börse München / free trade Börse Stuttgart / regulated ...
Further inquiry note: Otmar F. Winzig Vice President Investor Relations & Compliance Phone: +49 6151 92 1669 Email: otmar.winzig@softwareag.com Norbert Eder Vice President Corporate Communications Phone: +49 6151 92 1146 Email: norbert.eder@softwareag.com Branche: Software ISIN: DE0003304002 WKN: 330400 Index: TecDAX, CDAX, HDAX, Prime All Share, Technologie All ...
Ingelheim, Germany (ots/PRNewswire) - - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce sleep ...
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus(R) 80/25 in all 27 EU member states. It ...
Ingelheim, Germany (ots/PRNewswire) - - Results of 25,620 Patient Study ONTARGET(R) (ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial) Presented Today at the 57th Annual Scientific Session of the American College of Cardiology(1) - For Non-US Healthcare Media The results of the ...
Further inquiry note: Ulrich Brockmann, Head of Investor Relations, tel: +49 40 270 76 - 442 Branche: Retail ISIN: DE0005772206 WKN: 577220 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Stuttgart / free trade Börse Berlin / regulated ...
Further inquiry note: OMV Investor Relations: Ana-Barbara Kuncic Tel. +43 1 40 440-21443; e-mail: investor.relations@omv.com Press: Bettina Gneisz-Al-Ani Tel. +43 1 40 440-21660; e-mail: bettina.gneisz@omv.com Thomas Huemer Tel. +43 1 40 440-21660; e-mail: thomas.huemer@omv.com Internet Homepage: ...
Further inquiry note: ElringKlinger AG Kathrin Müller Tel. +49 (0) 7123/724-631 kathrin.mueller@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 9-month report/OMV/Oil/Gas/Austria 15.11.2007 - Clean net income after minorities of EUR 489 mn, up 22% against Q3/06; strong contribution from Borealis and Petrol Ofisi and lower effective ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information/Übernahme 29.10.2007 Adhoc - R E L E A S E PALFINGER takes over one of the global leaders in tail lift manufacturing o 100 percent acquisition of MBB Liftsystems AG o Considerable strengthening of the TAIL LIFT product ...
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
Norderstedt (ots) - One with a 7x optical zoom and 8.1 megapixels, the other with high ISO 6400 sensitivity and 10.1 megapixels Casio Europe GmbH and its parent company, Casio Computer Co., Ltd., released two new EXILIM digital cameras today. The EX-V8 features a slim yet powerful optical zoom like other models in the EXILIM Hi-Zoom series, and the EX-Z1080, ...
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. new product Kleinostheim (euro adhoc) - curasan AG, a German leader in regenerative medicine, has obtained FDA clearance for its REVOIS® All-in-One dental implant system, permitting the sale of the system in the U.S. This means that the system can be ...
Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...
- Net income more than doubled to 311 million (2005: 144m) - Dividend of 2.00 per share proposed, plus a special bonus of 0.50 - Sales grew 21 percent to 3.34 billion (2005: 2.76bn) - In 2007 focus on capacity expansion and continued growth in sales and earnings ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. balance Munich (euro adhoc) - ...
